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Background: About 39,000 patients were newly prescribed renal replacement therapy in Japan in 2011, resulting in
a total of more than 300,000 patients being treated with dialysis. This high prevalence of treated end stage kidney
disease (ESKD) patients is an emergent problem that requires immediate attention. We launched a prospective
cohort study to evaluate population specific characteristics of the progression of chronic kidney disease (CKD). In
this report, we describe the baseline characteristics and risk factors for cardiovascular disease (CVD) prevalence
among this cohort.
Methods: New patients from 16 nephrology centers who were older than 20 years of age and who visited or were
referred for the treatment of CKD stage 2–5, but were not on dialysis therapy, were recruited in this study. At enrollment,
medical history, lifestyle behaviors, functional status and current medications were recorded, and blood and urine
samples were collected. Estimated glomerular filtration rate (eGFR) was calculated by a modified three-variable equation.
Results: We enrolled 1138 patients, 69.6% of whom were male, with a mean age of 68 years. Compared with Western
cohorts, patients in this study had a lower body mass index (BMI) and higher proteinuria. The prevalence of CVD was
26.8%, which was lower than that in Western cohorts but higher than that in the general Japanese population.
Multivariate analysis demonstrated the following association with CVD prevalence: hypertension (adjusted odds ratio
(aOR) 3.57; 95% confidence interval (CI) 1.82-7.02); diabetes (aOR 2.45; 95% CI 1.86-3.23); hemoglobin level less than
11 g/dl (aOR 1.61; 95% CI 1.21-2.15); receiving anti-hypertensive agents (aOR 3.54; 95% CI 2.27-5.53); and statin therapy
(aOR 2.73; 95% CI 2.04-3.66). The combination of decreased eGFR and increased proteinuria was also associated with a
higher prevalence of CVD.
Conclusions: The participants in this cohort had a lower BMI, higher proteinuria and lower prevalence of CVD
compared with Western cohorts. Lower eGFR and high proteinuria were associated with CVD prevalence. Prospective
follow up of these study patients will contribute to establishment of individual population-based treatment of CKD.
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Chronic kidney disease (CKD) is a major global health
problem. In Japan, about 13% of the adult population,
i.e. approximately 13.3 million people, are estimated
to have CKD [1]. According to the National Health
and Nutrition Examination Survey (NHANES 1999–2004)
in the US, the reported prevalence of CKD was 13.1%,
which was a substantial increase over previous reports [2].
The incidence and prevalence of end stage kidney disease
(ESKD) is also rapidly increasing, with patients of ESKD
having to face the problems of poor outcome and high
cost of renal replacement treatment. In Japan, about
39,000 patients were introduced to renal replacement
therapy in 2011, resulting in more than 300,000 patients
on dialysis [3].
CKD is also a well-known risk factor for cardiovascu-
lar mortality and morbidity [4-6]. Reportedly, patients
with CKD are more likely to die of cardiovascular
disease (CVD) than of progression to ESKD [7]. CVD risk
factors, such as hypertension, diabetes and dyslipidemia,
tend to be highly prevalent and poorly controlled in
patients with CKD [8]. Studies have also shown that
estimated glomerular filtration rate (eGFR) and/or al-
buminuria are associated with cardiovascular (CV)
risk [9-11]. Thus, early recognition and treatment of
CKD are important to prevent CVD.
We established a large prospective cohort study of
Japanese people with CKD called the CKD-ROUTE
study (CKD Research of Outcomes in Treatment and
Epidemiology). The specific aim of the CKD-ROUTE
study is to evaluate the relationship of CKD progres-
sion, cardiovascular events and mortality to patient char-
acteristics, complications and treatment. The findings of
this study will contribute to development of appropriate
therapy for CKD in the Japanese population, whose char-
acteristics are quite different from Western populations.
The study is presently ongoing, although enrollment of
patients has been completed. In this report, we address
whether the basic characteristics and risk factors related
to CVD prevalence in Japanese patients are different from
those in other ethnic groups.
Methods
Study design and cohort participants
The CKD-ROUTE study is a prospective, observational
cohort of a representative Japanese population with
CKD stages 2–5 who are not on dialysis. Over 1000 par-
ticipants were enrolled at the Tokyo Medical and Dental
University Hospital and its 15 affiliated, larger than mid-
sized clinical centers located in the Tokyo metropolitan
area of Japan, where one third of the Japanese popula-
tion lives. Most patients were referred from primary care
clinics. At recruitment, written informed consent was
obtained from all patients and their eligibility wasdetermined. Approval for this study was obtained from
the ethics committees of all institutions participating in
the study (see Acknowledgments), and the research is be-
ing conducted in accordance with the ethical principles of
the Declaration of Helsinki. The protocol was registered
in UMIN Clinical Trials Registry (UMIN000004461).
Participants were eligible for inclusion if they: (1) newly
visited or were newly referred to the participant neph-
rology centers from October 2010 to December 2011;
(2) were over 20 years of age; and (3) had CKD stages
2 to 5 according to Kidney Disease Improving Global
Outcomes (KDIGO) classification [12]. Stage 5 CKD
patients were included in this study because a recent
study showed that 35% of CKD stage 5 patients did
not enter renal replacement therapy over a 3-year ob-
servation period [13]. The following patients were ex-
cluded from this study: (1) patients with malignancy
that was found or treated within the previous 2 years;
(2) transplant recipients; (3) patients with active gastro-
intestinal bleeding at enrollment; and (4) patients who did
not provide written informed consent. Participants have
been and will be followed up at 6-month intervals. The
total observation period is 3 years after enrollment or until
the start of dialysis, time of death, dropout from the study
or withdrawal of informed consent.
The primary study outcome is decline in renal func-
tion, defined by reduction in eGFR. Secondary outcomes
are incidence of CV events, initiation of dialysis, death,
hospitalization, bone fractures, and changes in the levels
of blood and urine biochemical measurements, blood
pressure, bodyweight and body mass index (BMI).
Sample size
One of the major endpoints of the CKD-ROUTE study
is initiation of dialysis. If the event rate of initiation of
dialysis is presumed to be about 30% according to the
rates shown in previous studies [13,14], in the case of
1000 subjects, the cumulative event number for the initi-
ation of dialysis is expected to be around 300. This will
have 80% power to detect a hazard ratio of 1.38 with a
significant difference of 5% or less. Therefore, we consid-
ered the necessary sample size of this study as 1000
subjects.
Measurements
At enrollment, medical history, lifestyle behaviors (self-
feeding ability) and current medications were recorded.
Anthropometric measurements (height and weight) were
obtained and BMI was calculated. Blood pressure (BP)
was measured using a standard sphygmomanometer.
Blood and urine samples were collected to measure
white blood cell, hemoglobin (Hb), platelet, total protein,
albumin, urea nitrogen, creatinine, sodium, potassium,
chloride, calcium, phosphorus, alkaline phosphatase,
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A1c (HbA1c), iron, unsaturated iron binding capacity,
ferritin, C-reactive protein, urinary occult blood, urinary
protein, and urinary creatinine. Estimated glomerular fil-
tration rate (eGFR) was calculated using the modified
three-variable Modification of Diet in Renal Disease
(MDRD) equation developed by the Japanese Society of
Nephrology to adjust for Japanese physical character-
istics: eGFR = 194 × serum creatinine− 1.094 × age− 0.287
(if female, × 0.739) [15]. Since the therapeutic targets
of treatment of renal anemia and dyslipidemia in the
Japanese CKD guidelines are Hb over 11 g/dl and
LDL-cholesterol below 120 mg/dl, respectively, anemia
and dyslipidemia were defined as Hb < 11 g/dl and
LDL-cholesterol ≥ 120 mg/dl [16]. Corrected calcium
(Ca) was adjusted for serum albumin using the equation:
Ca + (4 - serum albumin), if serum albumin was < 4g/dl. As
the normal range of intact PTH is 10–65 pg/ml as mea-
sured by ECLIA, high intact PTH was defined as levels over
65 pg/ml. Urinary protein to creatinine ratios (UPCR)
were measured because urinary albumin is not rou-
tinely measured due to a regulation of the Japanese
Medicare system, and were categorized as: optimal,
UPCR < 0.15 g/gCr (gram per gram creatinine);
high, UPCR 0.15-0.49 g/gCr; and very high, UPCR
≥ 0.5 g/gCr. This categorization is recommended by
Japanese CKD guidelines [17]. All participants are
basically treated according to the standard treatment pro-
tocols recommended by the Japanese CKD guidelines
[16,17].Definition of hypertension, diabetes, etiology of kidney
disease, and cardiovascular disease
Hypertension at entry was defined as systolic blood
pressure (SBP) ≥ 140 mmHg, diastolic blood pressure
(DBP) ≥ 90 mmHg, use of anti-hypertensive agents,
or history of being diagnosed with hypertension. Dia-
betes was defined as either HbA1c ≥ 6.5% (National
Glycohemoglobin Standardization Program (NGSP)
method) or receiving anti-diabetic therapy. Etiology of
kidney disease in each patient was determined by the
physician who was treating the patient at the time of
enrollment, based on patients’ past histories, clinical
characteristics and findings, and histological findings
in biopsied kidney specimens.
CVD was defined as a history of coronary heart
disease (angina pectoris (AP), myocardial infarction
(MI), or coronary revascularization), congestive heart
failure (CHF), peripheral arterial disease (PAD) (ne-
crosis, amputation or revascularization surgery), or
stroke (cerebral infarction, transient ischemic attack,
cerebral hemorrhage or subarachnoid hemorrhage).
Prevalence of CVD at enrollment represented acomposite of self-reported history of CVD or infor-
mation provided by previous doctors.Statistical analysis
Baseline characteristics are shown as mean ± standard
deviation and median with interquartile ranges for con-
tinuous variables, while categorical data are presented as
numbers and percentages. Analysis of variance and chi-
square test were used to compare continuous and categor-
ical variables across CKD stages, respectively. Multivariate
logistic regression analysis was used to identify the rela-
tionship between the composite CVD prevalence and pre-
dictor variables.
Statistical analyses were performed using SPSS, ver-
sion 20.0. P-value <0.05 was considered statistically
significant.Results
After excluding those who matched the exclusion criteria,
we enrolled 1138 patients in this cohort from October
2010 to December 2011. Although we did not accurately
count the number of those who were excluded in this
registry, we speculate that a less than 5% of the new CKD
stage 2–5 patients were excluded due to the exclusion
criteria.Baseline demographic characteristics and prevalence of
cardiovascular disease
The baseline demographic characteristics of the study
participants are shown in Table 1. Stage 3 was most
common (41.3%), followed by stage 4 and 5. Enrollment
of patients with stage 2 (8.3%) is a unique feature of this
cohort. Mean patient age was 68 years, and 69.6% were
male. Most patients were able to feed themselves
(99.1%). Mean BMI was 23.7 kg/m2, while 32.8% of them
were overweight (BMI ≥ 25 kg/m2). 37.1% of the patients
were diabetic. Although the percentage of patients with
diabetes was significantly higher in advanced CKD
stages, HbA1c was not significantly different among
CKD stages. Regarding the causes of CKD, the incidence
of diabetic nephropathy was higher in advanced CKD
stages, while nephrosclerosis and glomerulonephritis were
more frequent in moderate CKD stages. Nephrosclerosis
was the overall leading cause of CKD in this cohort,
through CKD stage 2–5. CVD was prevalent in 26.8%
of all the patients, and patients with advanced CKD
were more likely to have CVD, the prevalence being
35.7% in stage 4 and 30.6% in stage 5 patients. Re-
garding the individual causes of CVD, the incidence
of AP, MI, PAD and stroke were highest in stage 4
patients, the incidence of CHF gradually increasing
with CKD progression (Figure 1).
Table 1 Baseline demographics and prevalence of cardiovascular disease according to disease stage, the CKD-ROUTE
study (Oct 2010 - Dec 2011)
All Stage 2 Stage 3 Stage 4 Stage 5 P - value
n = 1138 n = 95 n = 470 n = 364 n = 209
Age (years old) 68 ± 14 57 ± 17 67 ± 13 71 ± 12 69 ± 14 <0.001
70 [61–77] 61 [46–71] 70 [60–76] 73 [64–78] 70 [61–78]
Male gender 792 57 361 255 119 <0.001
69.6% 60.0% 76.8% 70.1% 56.9%
Self-feeding ability 1118 94 460 360 204 0.744
99.1% 98.9% 99.1% 99.4% 98.6%
BMI (kg/m2) 23.7 ± 4.0 23.0 ± 4.0 23.7 ± 3.7 23.9 ± 4.1 23.8 ± 4.5 0.351
23.3 [21.0 - 25.8] 22.6 [20.6 - 25.4] 23.5 [21.3 - 25.7] 23.4 [21.0 - 26.4] 23.0 [20.9 - 25.6]
BMI≥ 25 kg/m2 328 20 129 115 64 0.473
32.8% 26.0% 32.0% 35.1% 33.2%
Diabetes 422 15 141 163 103 <0.001
37.1% 15.8% 30.0% 44.8% 49.3%
HbA1c (NGSP) (%) 6.1 ± 1.0 6.0 ± 1.1 6.1 ± 1.0 6.2 ± 1.0 6.1 ± 1.0 0.083
5.9 [5.6 - 6.5] 5.7 [5.5 - 6.1] 5.9 [5.6 - 6.4] 6.0 [5.6 - 6.6] 5.9 [5.5 - 6.5]
Albumin (g/dl) 4.0 ± 0.8 4.0 ± 0.6 3.8 ± 0.6 3.5 ± 0.6 3.8 ± 0.6 <0.001
4.3 [3.7 - 4.5] 4.1 [3.8 - 4.4] 3.9 [3.5 - 4.2] 3.6 [3.2 - 4.0] 4.0 [3.5 - 4.3]
eGFR (ml/min per 1.73 m2) 32.7 ± 18.7 72.1 ± 8.5 43.3 ± 8.2 22.0 ± 4.4 9.9 ± 3.0 <0.001
29.8 [17.5 - 45.0] 70.6 [64.9 - 79.7] 43.2 [35.5 - 50.2] 21.7 [17.9 - 25.6] 9.8 [7.4 - 12.4]
SBP (mmHg) 140 ± 22 139 ± 20 137 ± 22 140 ± 24 146 ± 22 <0.001
138 [125–152] 136 [125–150] 135 [122–150] 136 [125–154] 143 [136–160]
DBP (mmHg) 78 ± 15 83 ± 14 79 ± 15 75 ± 15 79 ± 15 <0.001
78 [68–87] 83 [74–92] 79 [70–87] 75 [64–83] 78 [69–90]
Causes of CKD
Diabetic nephropathy 287 10 74 116 87 <0.001
25.5% 10.5% 16.0% 32.0% 42.2%
Nephrosclerosis 451 23 214 159 55
40.0% 24.2% 46.2% 43.8% 26.7%
Glomerulonephritis 216 43 83 49 41
19.2% 45.3% 17.9% 13.5% 19.9%
Others 173 19 92 39 23
15.4% 20.0% 19.9% 10.7% 11.2%
Prevalence of CVD 305 7 104 130 64 <0.001
26.8% 7.4% 22.1% 35.7% 30.6%
Continuous variables are presented as mean ± standard deviation and median with interquartile ranges. Categorical data are presented as numbers (n) of patients
and percentages in each CKD stage. BMI body mass index, NGSP National Glycohemoglobin Standardization Program, eGFR estimated glomerular filtration rate,
SBP systolic blood pressure, DBP diastolic blood pressure, CVD cardiovascular disease.
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Table 2 shows the other CVD risk factors not shown in
Table 1. Overall, 90.2% of the participants had hyperten-
sion at enrollment, with significantly higher BP in pa-
tients with advanced CKD stages (Table 1 and 2).
The percentage of patients treated with angiotensin
II receptor blockers (ARB) or angiotensin convertingenzyme inhibitors (ACEI) was 63.3%, and calcium
channel blockers was 42.9%. The incidence of anti-
hypertensive agent usage was significantly higher in
advanced CKD groups.
Anemia (Hb < 11 g/dl) was present in 35.6% of the pa-
tients, the incidence being higher in advanced CKD stages.

















Figure 1 Prevalence of individual causes of cardiovascular
disease (CVD) stratified by CKD stages, the CKD-ROUTE study
(Oct 2010 - Dec 2011). Angina pectoris (AP), myocardial infarction
(MI), peripheral arterial disease (PAD) and stroke were highest in
patients with stage 4 CKD; congestive heart failure (CHF) incidence
gradually increased with CKD progression.
Table 2 Prevalence of non-renal risk factors for cardiovascula
(Oct 2010 - Dec 2011)
All Stage 2
n = 1138 n = 95
Hypertension 1027 69
90.2% 72.6%
Anti-hypertensive therapy 897 38
78.8% 40.0%
ARB or ACEI 720 29
63.3% 30.5%
Calcium channel blockers 488 13
42.9% 13.7%
β blockers 163 3
14.3% 3.2%





Hb (g/dl) 13.7 ± 1.9 13.1 ± 1.9
13.9 [12.8 - 14.9] 13.2 [11.9 - 14.3]
Hb < 11 g/dl 404 7
35.6% 7.4%
Iron deficiency 142 6
14.9% 7.9%
Oral iron supplementation 58 1
5.1% 1.1%
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dence being highest in stage 4 patients. The percentage of
patients receiving oral iron supplementation and erythro-
poiesis stimulating agents (ESA) increased in advanced
CKD groups.
A trend existed between decreasing eGFR and the in-
creasing percentage of patients with low HDL-cholesterol.
The percentage of patients with high LDL-cholesterol
was higher in stage 2 and stayed relatively low through
stages 3 to 5. Statin therapy was prescribed in 28.6% of
patients, the percentage significantly increasing in ad-
vanced CKD groups.
Low corrected serum calcium levels (< 8.4 mg/dl) and
high phosphorus levels (≥ 4.6 mg/dl) were seen in pa-
tients with stage 5 CKD. The percentage of patients with
high intact PTH levels (> 65 pg/ml) was 15.9% in stage
2, 32.2% in stage 3, 68% in stage 4 and 95.5% in stage 5
CKD, respectively. On urinalysis, UPCR was significantly
higher in advanced CKD stages, with 90% of stage 5
CKD patients having a UPCR over 0.5 g/gCr.r disease at enrollment, the CKD-ROUTE study
Stage 3 Stage 4 Stage 5 P - value
n = 470 n = 364 n = 209
406 348 204 <0.001
86.4% 95.6% 97.6%
337 326 196 <0.001
71.7% 89.6% 93.8%
282 271 138 <0.001
60.0% 74.5% 66.0%
173 180 122 <0.001
36.8% 49.5% 58.4%
57 66 37 <0.001
12.1% 18.1% 17.7%
22 36 18 0.001
4.7% 9.9% 8.6%
107 156 112 <0.001
22.8% 42.9% 53.6%
11.2 ± 1.9 9.8 ± 1.5 11.9 ± 2.3 <0.001
11.1 [9.9 - 12.4] 9.8 [8.8 - 10.7] 12.0 [10.2 - 13.6]
64 169 164 <0.001
13.6% 46.6% 78.5%
46 61 29 0.013
12.2% 19.7% 15.3%
12 23 22 <0.001
2.6% 6.3% 10.5%
Table 2 Prevalence of non-renal risk factors for cardiovascular disease at enrollment, the CKD-ROUTE study
(Oct 2010 - Dec 2011) (Continued)
ESA 121 1 5 48 67 <0.001
10.6% 1.1% 1.1% 13.2% 32.1%
Lipid abnormalities
Total cholesterol (mg/dl) 218 ± 49 197 ± 48 185 ± 46 190 ± 51 194 ± 49 <0.001
214 [190–248] 193 [169–216] 182 [153–217] 180 [153–220] 190 [162–220]
HDL-C (mg/dl) 61 ± 20 55 ± 17 50 ± 16 51 ± 17 52 ± 17 <0.001
59 [45–67] 52 [42–63] 48 [39–59] 48 [38–59] 50 [40–62]
HDL-C < 40 mg/dl 229 11 76 89 53 <0.001
22.5% 12.8% 18.2% 27.7% 27.7%
LDL-C (mg/dl) 128 ± 42 111 ± 40 104 ± 39 109 ± 42 110 ± 41 <0.001
124 [106–152] 108 [87–130] 101 [75–125] 102 [78–126] 107 [83–130]
LDL-C≥ 120 mg/dl 317 45 133 84 55 <0.001
34.6% 58.4% 34.5% 29.8% 31.8%
Statin 325 16 112 117 80 <0.001
28.6% 16.8% 23.8% 32.1% 38.3%
Disorders of mineral metabolism
Corrected Ca (mg/dl) 9.6 ± 0.5 9.5 ± 0.4 9.3 ± 0.5 9.2 ± 0.9 9.4 ± 0.6 <0.001
9.6 [9.3 -9.9] 9.5 [9.2 - 9.8] 9.3 [9.0 - 9.6] 9.2 [8.8 - 9.5] 9.4 [9.1 - 9.7]
Corrected Ca < 8.4 mg/dl 32 1 2 8 21 <0.001
2.9% 1.1% 0.4% 2.3% 10.2%
P (mg/dl) 3.3 ± 0.5 3.3 ± 0.6 3.5 ± 0.6 4.6 ± 1.3 3.6 ± 0.9 <0.001
3.4 [3.0 - 3.6] 3.3 [3.0 - 3.6] 3.5 [3.1 - 3.9] 4.4 [3.7 - 5.3] 3.5 [3.1 - 4.0]
P≥ 4.6 mg/dl 102 0 6 14 82 <0.001
9.4% 0.0% 1.3% 4.0% 40.2%
Intact PTH (pg/ml) 46 ± 22 59 ± 37 103 ± 63 246 ± 156 109 ± 108 <0.001
39 [33–56] 51 [37–71] 89 [60–129] 218 [138–313] 71 [45–129]
Intact PTH > 65 pg/ml 496 11 116 200 169 <0.001
55.1% 15.9% 32.2% 68.0% 95.5%
Urinalysis
UPCR (g/gCr) 2.16 ± 3.23 1.40 ± 3.08 1.21 ± 2.48 2.37 ± 3.04 4.31 ± 3.99 <0.001
0.74 [0.13 - 2.85] 0.26 [0.07 - 1.14] 0.24 [0.06 - 0.99] 1.09 [0.23 - 3.40] 3.16 [1.15 - 6.16]
UPCR≥ 0.5 g/gCr 591 36 159 224 172 <0.001
56.3% 40.0% 36.7% 66.7% 90.1%
Continuous variables are presented as mean ± standard deviation and median with interquartile ranges. Categorical data are presented as numbers (n) of patients
and percentages in each CKD stage. ARB angiotensin receptor blockers, ACEI angiotensin converting enzyme inhibitors, Hb hemoglobin, ESA erythropoiesis
stimulating agent, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG triglycerides, Ca calcium, P phosphorus, PTH
parathyroid hormone, UPCR urinary protein to creatinine ratio, g/gCr gram per gram creatinine.
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The results of multiple logistic regression analysis of the
risk factors that predict the prevalence of CVD at enroll-
ment are shown in Table 3. Odds ratio was adjusted for
age and gender. Hypertension, diabetes, advanced CKD
stage and UPCR greater than 0.5 g/gCr were associated
with high CVD prevalence. Receiving anti-hypertensive
agents was associated with CVD prevalence. However,
SBP over 130 mmHg at the first visit was not associatedwith CVD. Anemia (Hb < 11 g/dl), iron deficiency, use of
oral iron supplementation and ESA were also associated
with the prevalence of CVD. Low HDL-cholesterol and
receiving lipid lowering therapy (use of statins) were as-
sociated with CVD. However, the odds ratio of LDL-
cholesterol ≥ 120 mg/dl was 0.49, indicating that low
LDL-cholesterol was associated with CVD risk. Hyper-
parathyroidism (intact PTH > 65 pg/ml) was found to be
associated with CVD. However, low corrected serum
Table 3 Risk factors for the presence of cardiovascular disease, the CKD-ROUTE study (Oct 2010 - Dec 2011)
Unadjusted OR [95% CI] P- value Adjusted OR [95% CI] P - value
Hypertension 4.07 [2.10 - 7.90 ] <0.001 3.57 [1.82 - 7.02] <0.001
Diabetes 2.32 [1.77 - 3.03] <0.001 2.45 [1.86 - 3.23] <0.001
BMI
Optimal BMI (18.5 to 24.9 kg/m2) 1 (reference) 1 (reference)
≥ 25 kg/m2 1.10 [0.82 - 1.49] 0.513 1.27 [0.93 - 1.74] 0.130
< 18.5 kg/m2 0.77 [0.43 -1.39] 0.391 0.74 [0.40 - 1.36] 0.329
CKD stage
Stage 2 1 (reference) 1 (reference)
Stage 3 3.57 [1.61 - 7.95] 0.002 2.56 [1.14 - 5.78] 0.023
Stage 4 6.98 [3.14 - 15.53] <0.001 4.79 [2.12 - 10.81] <0.001
Stage 5 5.55 [2.43 - 12.65] <0.001 4.37 [1.89 - 10.11] 0.001
UPCR
< 0.15 g/gCr 1 (reference) 1 (reference)
0.15 to 0.49 g/gCr 1.21 [0.78 - 1.89] 0.402 1.23 [0.78 - 1.94] 0.378
≥ 0.5 g/gCr 1.55 [1.11 - 2.16] 0.009 1.77 [1.26 - 2.50] 0.001
SBP≥ 130 mmHg 0.90 [0.68 - 1.18] 0.438 0.93 [0.70 - 1.23] 0.600
Anti-hypertensive therapy 3.92 [2.53 - 6.07] <0.001 3.54 [2.27 - 5.53] <0.001
Use of ARB or ACEI 1.72 [1.29 - 2.29] <0.001 1.64 [1.22 - 2.20] 0.001
Use of calcium channel blocker 1.55 [1.19 - 2.02] 0.001 1.55 [1.18 - 2.03] 0.002
Use of diuretics 1.61 [1.08 - 2.38] 0.019 2.44 [1.84 - 3.24] <0.001
Hb < 11 g/dl 1.63 [1.24 - 2.13] <0.001 1.61 [1.21 - 2.15] 0.001
Iron deficiency 2.03 [1.40 - 2.94] <0.001 2.41 [1.63 - 3.58] <0.001
Use of ESA 2.10 [1.43 - 3.10] <0.001 1.93 [1.29 - 2.89] 0.001
Use of oral iron supplementation 2.01 [1.17 - 3.44] 0.011 2.15 [1.22 - 3.80] 0.008
LDL-C≥ 120 mg/dl 0.44 [0.31 - 0.61] <0.001 0.49 [0.34 - 0.68] <0.001
HDL-C < 40 mg/dl 2.45 [1.80 - 3.35] <0.001 2.29 [1.66 - 3.16] <0.001
TG≥ 150 mg/dl 0.81 [0.61 - 1.08] 0.149 0.92 [0.69 - 1.23] 0.575
Use of statin 2.48 [1.88 - 3.27] <0.001 2.73 [2.04 - 3.66] <0.001
Corrected Ca < 8.4 mg/dl 0.49 [0.19 - 1.30] 0.152 0.46 [0.17 - 1.22] 0.118
P ≥ 4.6 mg/dl 1.12 [0.72 - 1.76] 0.611 1.34 [0.84 - 2.14] 0.214
Intact PTH > 65 pg/ml 1.80 [1.33 - 2.43] <0.001 1.86 [1.36 - 2.54] <0.001
Odds ratio (OR) was adjusted by age and gender. CI confidence interval, BMI body mass index, UPCR urinary protein to creatinine ratio, g/gCr gram per gram
creatinine, SBP systolic blood pressure, ARB angiotensin receptor blockers, ACEI angiotensin converting enzyme inhibitors, Hb hemoglobin, ESA erythropoiesis
stimulating agent, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG triglycerides, Ca calcium, P phosphorus, PTH
parathyroid hormone.
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http://www.biomedcentral.com/1471-2369/14/152calcium (< 8.4 mg/dl) and high serum phosphorus (≥ 4.6
mg/dl) were not associated with CVD risk. In addition,
since we sometimes encounter patients with CHF that is
unrelated to atherosclerotic diseases, we analyzed the
factors associated with the prevalence of CVD that
excludes CHF from the definition. All the risk factors
were still significant, except for three factors, namely,
anemia, use of ESA and use of oral iron supplementa-
tion (Additional file 1: Table S1).Figure 2 shows the prevalence of CVD in 11 categories
classified based on CKD stages and proteinuria. Pa-
tients with stage 4 and 5 CKD with very high protein-
uria were significantly associated with the prevalence of
CVD.
Discussion
The CKD-ROUTE study was established to identify the
risk factors of CKD and effects of treatment on its
0.01 0.1 1 10 100
CKD Stage Proteinuria n Unadjusted OR [95% CI] Adjusted OR [95% CI] 
Stage 2 Optimal 38 1 (reference) 1 (reference)
High 16 0.78 [0.07-8.10] 1.01 [0.10-10.77] 
Very high 36 1.06 [0.20-5.63] 1.01 [0.19-5.46] 
Stage 3 Optimal 179 2.74 [0.79-9.42] 1.91 [0.55-6.71] 
High 95 4.17 [1.18-14.75] 2.99 [0.83-10.78] 
Very high 159 3.41 [0.99-11.75] 2.80 [0.80-9.79] 
Stage 4 Optimal 64 6.11 [1.69-22.13] 3.77 [1.02-13.98] 
High 48 4.80 [1.27-18.22]  2.91 [0.75-11.28] 
Very high 224 7.55 [2.25-25.3] 5.60 [1.65-19.08] 
Stage 5 Optimal & High 19 5.38 [1.17-24.75] 3.67 [0.78-17.38] 
Very high 172 4.78 [1.41-16.26] 3.88 [1.12-13.44] 
Figure 2 Prevalence of cardiovascular disease (CVD) in 11 categories classified by CKD stages and proteinuria, the CKD-ROUTE study
(Oct 2010 - Dec 2011). Odds ratio (OR) was adjusted for age and gender. The reference category is the group with stage 2 and optimal
proteinuria. Horizontal lines indicate 95% confidence intervals (95% CI) and the scales are logarithmic. eGFR lower than 30 ml/min per 1.73 m2
and very high proteinuria were significantly associated with the prevalence of CVD.
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http://www.biomedcentral.com/1471-2369/14/152progression. A unique characteristics of this study is that
all enrolled patients are those who newly visited or were
referred to our nephrology centers. This gives us infor-
mation on the basic characteristics of the patients before
they receive specific treatment from nephrologists,
allowing clear evaluation of the efficacy of the treatment
by nephrologists in a prospective manner. Although the
dietary habits in Japan have been westernized, there are
many differences between Japanese compared to Western
populations, such as lower calorie intake, smaller body
size and lower BMI [18,19]. It is highly possible that these
differences affect the progression and treatment of CKD.
The ROUTE study has the potential to help establish
ethnic group-based CKD guidelines.
Keeping such differences in mind, at the completion of
the enrollment, we addressed whether the basic charac-
teristics of ROUTE patients are different from those of
Western cohorts, such as those in the CRIC study in the
US [20,21], CRISIS study in UK [22], and MERENA
study in Spain [23]. As shown in Table 4, ROUTE partic-
ipants were older, with a lower BMI, lower prevalence of
diabetes, higher SBP and DBP, and lower prevalence
of CVD. Thus, the patients in this cohort differ from
Western populations in many aspects, with some of
these differences probably reflecting basic physical and ha-
bitual differences among the ethnic groups.
Although the prevalence of CVD in ROUTE partici-
pants is lower than that in Western CKD cohorts
(Table 4), it is still higher than that in the general Japa-
nese population [24]. As summarized in Tables 1 and 2,
many established risk factors of CVD showed a highprevalence in this cohort, with an increase in the preva-
lence of CVD with worsening CKD stage. We analyzed
which factors could predict the prevalence of CVD at
enrollment. This analysis is important because the deter-
mined factors in turn may predict the future occurrence
of new CV events. As summarized in Table 3, many fac-
tors predicted the CVD prevalence at enrollment, some
of which are discussed below.
As expected, hypertension and diabetes were associ-
ated with CVD prevalence. Although receiving anti-
hypertensive therapy was an associated factor for CVD,
SBP ≥ 130 mmHg at enrollment was not a significant
predictor. This could be explained by the fact that pa-
tients with CVD were already prescribed anti-
hypertensive drugs by primary care physicians, resulting
in normalized BP. Interestingly, the adjusted odds ratio
for the use of diuretics was higher than for other anti-
hypertensive agents. A most likely explanation for this
would be that participants with CVD have been pre-
scribed diuretics for treatment of CHF or edema. Al-
though not shown, the fact that 78.7% of the patients
who experienced CHF used diuretics supports this
explanation.
Increasing UPCR was also associated with the preva-
lence of CVD. Furthermore, as shown in Figure 2, the
combination of advanced CKD stage and high protein-
uria was significantly associated with CVD prevalence. It
is of note that the amount of urinary protein excretion
was high in ROUTE patients compared with the partici-
pants of Western CKD cohorts (Table 4). The reason for
this is not immediately clear, but relatively poor control
Table 4 Comparison of baseline characteristics of CKD cohort studies
ROUTE CRIC [20,21] CRISIS [22] MERENA [23]
Japan US UK Spain
n = 1138 n = 3612 n = 1325 n = 1129
eGFR (ml/min per 1.73 m2) 0 - 90 20 - 70 10 - 60 15 - 60
Age (years) 68 58.2 65.1 68
Male gender (%) 69.6 54 63.7 64
BMI (kg/m2) 23 32.1 28.4
eGFR (ml/min per 1.73 m2) 32.7 43.4 30.9 28
Diabetes (%) 37.1 47 32.4 40.8
Hypertension (%) 90.2 86 92.7
SBP (mmHg) 140 127.7 138.3 141
DBP (mmHg) 78 71.4 75.2 76
ARB or ACEI (%) 63 68 59.8
Hb (g/dl) 11.9 12.7 12.41 12.8
LDL-C (mg/dl) 110 102.5 116
Ca (mg/dl) 9.1 9.2 9.14
P (mg/dl) 3.6 3.7 3.72 3.7
Intact PTH (pg/ml) 109 53 93.2 145
Prevalence of CVD (%) 26.8 33.4 47.2 39.1
Proteinuria (mean) 2.16 g/gCr 1.08 g/day 1.2 g/day
Proteinuria (median) 0.74 g/gCr 0.17 g/day
BMI body mass index, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, ARB angiotensin receptor blockers,
ACEI angiotensin converting enzyme inhibitors, Hb hemoglobin, LDL-C low density lipoprotein cholesterol, Ca calcium, P phosphorus, PTH parathyroid hormone,
CVD cardiovascular disease, g/gCr gram per gram creatinine.
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http://www.biomedcentral.com/1471-2369/14/152of BP may partly account for this. Also, the fact that the
participants were new patients not previously treated by
nephrologists, and were not given specific treatments
could have contributed to this difference.
Dyslipidemia is a conventional CV risk factor that is
also commonly observed in CKD patients, with an in-
creasing incidence with progression of CKD stage [25].
Statins are the most important pharmacologic approach
altering cholesterol levels, with more than one fourth of
the patients in this study being treated by statins. Our
data showed that although statin therapy was an associ-
ated factor for CVD, high LDL-cholesterol levels were
not, suggesting that patients who had CVD were already
prescribed lipid lowering drugs by primary care physi-
cians, same as anti-hypertensive drugs.
Anemia was also an associated factor of CVD preva-
lence in this study. Patients with eGFR below 60 ml/min
per 1.73 m2 are much more likely to have anemia, and
the prevalence and severity of anemia increases with de-
clining kidney function [26]. In the present study, more
than almost half of the CKD stage 4 and 5 patients had
anemia (Hb < 11g/dl), with an incidence of iron defi-
ciency of 19.7% and 15.3% in these stages, respectively.
However, the percentage of patients receiving oral iron
or ESA therapy was only 5% and 10%, respectively,reflecting insufficient treatment by primary care physi-
cians. Follow up of the cohort by nephrologists for ad-
equate treatment will provide for the effect of treatment
of anemia in CKD patients.
Conclusions
The ROUTE participants were characterized by low
BMI, high proteinuria and low prevalence of CVD.
Hypertension, diabetes, anemia, decreasing eGFR and
increasing proteinuria are associated with the prevalence
of CVD. Receiving anti-hypertensive agents, statin ther-
apy and treatment for anemia are also associated with
the prevalence of CVD. Prospective follow up of ROUTE
participants treated by nephrologists will provide high
quality evidence of the risk factors of progression of
CKD and their appropriate treatment.
Additional file
Additional file 1: Table S1. Risk factors for the presence of
cardiovascular disease excluding congestive heart failure, CKD-ROUTE
study (Oct 2010 - Dec 2011).
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